Progress in Neuro-Psychopharmacology and Biological Psychiatry
Methodological requirements for clinical trials in refractory epilepsies — our experience with zonisamide
References (13)
Proposal for revised clinical and electroencephalographic classification of epileptic seizures
Epilepsia
(1981)Guidelines for clinical evaluation of antiepileptic drugs
Epilepsia
(1989)- et al.
Phase II study of zonisamide (ZNA), a new antiepileptic drug, in epileptic children
Jpn J Pediatr
(1987) - et al.
Pharmacokinetic studies of AD-810, a new antiepileptic compound — phase I trials
Arzneimittileforschung
(1982) - et al.
Absorption, distribution and excretion of 3-(sulfamoyl 14C methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men
Arzneimittelforschung
(1983) - et al.
Phase III study of a new antiepileptic AD-810, zonisamide in childhood epilepsy
Jpn J Pediatr
(1988)
Cited by (73)
Efficacy, tolerability, and safety of zonisamide in children with epileptic spasms: A systematic review and meta-analysis.
2021, SeizureCitation Excerpt :Lethargy (8/15), irritability (5/15), gastroenteritis (2/15), dryness of skin and mouth (1/15), loss of appetite (1/15), and metabolic acidosis (1/15) were predominant adverse effects of zonisamide. Yagi et al [19]. have explored the efficacy of zonisamide in nine patients with epileptic spasms, out of which 2 patients had >50% reduction in spasms, but further details of these patients have not been described in the study.
Clinical opinion: Earlier employment of polytherapy in sequential pharmacotherapy of epilepsy
2019, Epilepsy ResearchCitation Excerpt :Benzodiazepine derivatives are broad-spectrum AEDs being used in both FS and GS, however, they are considered second-line drugs being useful in adjunctive therapy, which may be related to their sedating side effects and potential tachyphylaxis (Callaghan and Goggin, 1988; Specht et al., 1989; Canadian Clobazam Cooperative Group, 1991). Since introduction of CBZ and VPA in late 1960′s, which were major drugs during the era of conventional drug, there was a long hibernation period in the new drug development for epilepsy until the marketing approval of vigabatrin (VGB) in UK and zonisamide (ZNS) in Japan in 1989 (Sander et al., 1990; Yagi and Seino, 1992), which opened the “Era of New AEDs” (Allen, 1995). Seventeen new drugs have been introduced to the market until now and we have at least 25 AEDs, including both conventional and new AEDs, to use in our practice, which is completely a different environment for pharmacotherapy of epilepsy from the era of conventional AEDs (Santulli et al., 2016; Shih et al., 2017).
Zonisamide for refractory juvenile absence epilepsy
2014, Epilepsy ResearchCitation Excerpt :Different studies have shown a positive effect in the treatment of AS but these studies included heterogeneous group of patients with different types of generalized epilepsies and with a clear predominance of children (Zaccara and Specchio, 2009). The efficacy of ZNS on AS has been shown for the first time in a small series of patients in a prospective study (Yagi and Seino, 1992). Later, Yamauchi and Aikawa (2004) in their post-marketing surveillance study reported that the responder rate (proportion of patients with at least 50% seizure reduction) was 87.5% (n = 8) for typical absences and 46.3% (n = 54) for atypical absences.
A prospective audit of adjunctive zonisamide in an everyday clinical setting
2010, Epilepsy and BehaviorVoltage-gated calcium channels in the etiopathogenesis and treatment of absence epilepsy
2010, Brain Research ReviewsZonisamide block of cloned human T-type voltage-gated calcium channels
2009, Epilepsy Research